

WHO Position Paper on Hepatitis B vaccines

Some selected references

(chronological order under each subheading)

Agent and disease

EASL Clinical Practice Guidelines: Management of chronic hepatitis B. *Journal of Hepatology*, 2009, 50:227-242.

Lok AS and McMahon BJ, AASLD Practice Guidelines: Chronic Hepatitis B: Update 2009. *Hepatology*, 2009, 50:1-36.

Amirzargar AA et al. HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine. *Iranian Journal of Immunology*, 2008, 5:92-99.

La Torre G, Nicolotti N, de Waure C, Chiaradia G, Specchia ML, Mannocci A, Ricciardi W. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. *Virology*. 2008 Jul 24;5(1):84.

Nagao Y, Matsuoka H, Kawaguchi T, Ide T, Sata M. HBV and HCV infection in Japanese dental care workers. *Int J Mol Med*. 2008 Jun;21(6):791-9

Xu YY, Yu JY, Zhong YW, Song HB, Liu HH, Jia LL, Li SL, Xu JQ, Li Q. Association between the frequency of class II HLA antigens and the susceptibility to intrauterine infection of hepatitis B virus. *Int J Biol Sci*. 2008 Apr 25;4(2):111-5

Velu V, Saravanan S, Nandakumar S, Dhevahi E, Shankar EM, Murugavel KG, Kumarasamy T, Thyagarajan SP. Transmission of "a" determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. *Jpn J Infect Dis*. 2008 Jan;61(1):73-6.

Liaw YF et al. APASL Guidelines for HBV Management. *Hepatology International*, 2008,2:263-283.

Velu V, Saravanan S, Nandakumar S, Dhevahi E, Shankar EM, Murugavel KG, Kumarasamy T, Thyagarajan SP. Transmission of "a" determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. *Jpn J Infect Dis*. 2008 Jan;61(1):73-6.

Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. *J Acquir Immune Defic Syndr*. 2007 Nov 1;46(3):279-82.

AD Sayiner AA, Agca H, Sengonul A, Celik A, Akarsu M. A new hepatitis B virus vaccine escape mutation in a renal transplant recipient. *J Clin Virol.* 2007 Feb;38(2):157-60.

Keeffe EB. Hepatitis a and B superimposed on chronic liver disease: vaccine-preventable diseases. *Trans Am Clin Climatol Assoc.* 2006;117:227-38.

Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. *Vaccine.* 2006 Jan 30;24(5):572-7.

McMahon BJ. Epidemiology and natural history of hepatitis B. *Semin Liver Dis.* 2005;25 Suppl 1:3-8.

Boxall EH, Sira J, Standish RA, Davies P, Sleight E, Dhillon AP, Scheuer PJ, Kelly DA. Natural history of hepatitis B in perinatally infected carriers. *Arch Dis Child Fetal Neonatal Ed.* 2004 Sep;89(5):F456-60.

Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. *Semin Liver Dis.* 2003 Feb;23(1):5-20.

Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. *Vaccine.* 2003 Dec 1;21(32):4626-49.

Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. *Clin Infect Dis.* 1995 Apr;20(4):992-1000.

McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. : *J Infect Dis.* 1985 Apr;151(4):599-603.

Beasley RP, Trepo C, Stevens CE, Szmunness W. The e antigen and vertical transmission of hepatitis B surface antigen. *Am J Epidemiol.* 1977 Feb;105(2):94-8.

Epidemiology

(WHO 2009). Global and regional immunization profile. Geneva, World Health Organization, Vaccine-preventable diseases monitoring system, 2009 http://www.who.int/immunization_monitoring/en/globalsummary/GS_GLOProfile.pdf, accessed 4 September 2009).

(WHO 2009). Global Plan of Action on Workers' Health 2008–2017, Objective 1.10 (WHA60/A60_R26): http://apps.who.int/gb/ebwha/pdf_files/WHA60/A60_R26-en.pdf.

WHO. International travel and health. 2009, p 106. ISBN-13 9789241580427 <http://www.who.int/topics/travel/en/>

Weinbaum CM, Lyerla R, Mackellar DA, Valleroy LA, Secura GM, Behel SK, Bingham T, Celentano DD, Koblin BA, Lalota M, Shehan DA, Thiede H, Torian LV; Young Men's Survey Study Group. The Young Men's Survey phase II: hepatitis B immunization and infection among young men who have sex with men. *Am J Public Health*. 2008 May;98(5):839-45. Epub 2008 Apr 1.

Koya DL, Hill EG, Darden PM. The effect of vaccinated children on increased hepatitis B immunization among high-risk adults. *Am J Public Health*. 2008 May;98(5):832-8.

Dumolard L et al. Implementation of Newborn Hepatitis B Vaccination - Worldwide, 2006. *Morbidity and Mortality Weekly Report*, 2008, 57:1249-1252.

Sutton AJ, Gay NJ, Edmunds WJ, Gill ON. Modelling alternative strategies for delivering hepatitis B vaccine in prisons: the impact on the vaccination coverage of the injecting drug user population. *Epidemiol Infect*. 2008 Mar 17:1-6.

Steedman NM, McMillan A. Hepatitis B testing and vaccination in patients recently diagnosed with HIV infection. *Int J STD AIDS*. 2008 Feb;19(2):83-4..

Murhekar MV, Murhekar KM, Sehgal SC. Epidemiology of hepatitis B virus infection among the tribes of Andaman and Nicobar Islands, India. *Trans R Soc Trop Med Hyg*. 2008 Aug;102(8):729-34.

Pitigoi D, Rafila A, Pistol A, Arama V, Molagic V, Streinu-Cercel A. Trends in hepatitis B incidence in Romania, 1989-2005. *Euro Surveill*. 2008 Jan 10;13(2). pii: 8012.

Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, Paupunwatana S, Chaiear K, Khwanjaipanich S, Poovorawan Y. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. *Trop Med Int Health*. 2006 Oct;11(10):1496-502.

Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. *Liver Int*. 2005 Aug;25(4):696-703.

Goldstein ST et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. *International Journal of Epidemiology*, 2005, 34:1329–1339.

Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, Flenor M, Ryder PL, Margolis HS. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. *J Infect Dis*. 2002 Mar 15;185(6):713-9.

Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, Mutton KJ, Syed Q. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. *J Infect*. 1998 Nov; 37(3):260-9.

Kant L, Hall AJ. Epidemiology of childhood hepatitis B in India: vaccination related issues. *Indian J Pediatr*. 1995 Nov-Dec;62(6):635-53.

Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. *Semin Liver Dis*. 1991 May;11(2):84-92.

Beasley RP, Hwang LY. Overview of the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis HS, eds. *Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: contemporary issues and future prospects.* Baltimore, Williams & Wilkins, 1991: 532–535.

Vaccine, immunogenicity, efficacy and effectiveness

Nemes E, Lefler E, Szegedi L, Kapitány A, Kovács JB, Balogh M, Szabados K, Tumpek J, Sipka S, Korponay-Szabó IR. Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease. *Pediatrics.* 2008 Jun;121(6):e1570-6.

Amirzargar AA, Mohseni N, Shokrgozar MA, Arjang Z, Ahmadi N, Yousefi Behzadi M, Amanzadeh A, Shokri F. HLA-DRB1, DQA1 and DQB1 Alleles and Haplotypes Frequencies in Iranian Healthy Adult Responders and Non-Responders to Recombinant Hepatitis B Vaccine. *Iran J Immunol.* 2008 Jun;5(2):92-9.

Weihrauch MR, von Bergwelt-Baildon M, Kandic M, Weskott M, Klamp W, Rosler J, Schultze JL. T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. *World J Gastroenterol.* 2008 Apr 28;14(16):2529-33.

de la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. *Int J Infect Dis.* 2008 Mar;12(2):183-9.

Fernandes SJ, Shlessarenko N, Souto FJ. Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. *Vaccine.* 2008 Feb 20;26(8):1032-7.

Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. *Vaccine.* 2008 Jan 10;26(2):269-76.

Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. *J Med Virol.* 2006 Feb;78(2):169-77.

Lee C et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. *Cochrane Database of Systematic Reviews,* 2006,(2):CD004790.

Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. *Cochrane Database Syst Rev.* 2005 Oct 19;(4):CD000100.

Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. *Clin Infect Dis.* 2002 Dec 1;35(11):1368-75.

Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. *Vaccine.* 2002 Nov 1;20(31-32):3739-43.

Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. *BMJ*. 2002 Sep 14;325(7364): 569.

Hieu NT, Kim KH, Janowicz Z, Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. *Vaccine*. 2002 Mar 15;20(13-14):1803-8.

Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? *J Infect Dis*. 1999 Feb;179(2):489-92.

Viviani S et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. *Vaccine*, 1999,17:2946-2950.

Averhoff F et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. *American Journal of Preventive Medicine*, 1998,15:1-8.

Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med*. 1997 Jun 26;336(26):1855-9.

Lee CL, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. *Pediatrics*. 1997 Mar;99(3):351-3.

Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. *JAMA*. 1996 Sep 18;276(11):906-8.

Khukhlovich PA, Shakhgil'dian IV, Narkevich MI, Anan'ev VA, Kuzin SN, Sergeeva NA, et al. [The vaccinal prophylaxis of hepatitis B among children born to mothers with persistent HBs-antigenemia]. *Zhurnal Mikrobiologii, Epidemiologii, Immunobiologii* 1996; 2:55-9.

Kang P, Shen XM, Yu HM. [Study on the efficacy of genetically engineered vaccines against hepatitis B for interruption of perinatal transmission] *Zhonghua Hu Li Za Zhi*. 1995 Jul 5;30(7):390-2. [Article in Chinese]

Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. *J Pediatr*. 1995 May;126(5 Pt 1):716-21.

Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. *The Journal of Infectious Diseases* 1995;171(1):54-60.

Tan KL et al. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. *Journal of the American Medical Association*, 1994,271:859-861.

Assateerawatt A, Tanphaichitr VS, Suvatte V, Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. *Asian Pac J Allergy Immunol*. 1993 Jun;11(1):85-91.

Grosheide PM, del Canho R, Heijtkink RA, Nuijten AS, Zwijnenberg J, Bänffer JR, Wladimiroff YW, Botman MJ, Mazel JA, de Gast GC, et al. Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. *Am J Dis Child*. 1993 Dec;147(12):1316-20.

Halliday ML, Kang LY, Rankin JG, Coates RA, Corey PN, Hu ZH, Zhou TK, Yuan GJ, Yao FL. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China. *Int J Epidemiol*. 1992 Jun;21(3):564-73.

Sehgal A, Gupta I, Sehgal R, Ganguly NK. Hepatitis B vaccine alone or in combination with anti-HBs immunoglobulin in the perinatal prophylaxis of babies born to HBsAg carrier mothers. *Acta Virol*. 1992 Aug;36(4):359-66.

Sehgal A, Sehgal R, Gupta I, Bhakoo ON, Ganguly NK. Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection. *J Trop Pediatr*. 1992 Oct;38(5):247-51.

Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapelière P, Safary A. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Efficacy/effectiveness trials. *Pediatr Infect Dis J*. 1992 Oct;11(10):816-21.

Theppisai U, Thanuntaseth C, Chiewsilp P, Siripoonya P. Prevention of hepatitis B infection in infants born to hepatitis B carrier mothers: low dosage vaccination. *Int J Gynaecol Obstet*. 1990 Aug;32(4):353-7.

Ip HM, Wong VC, Lelie PN, Reesink HW, Schaasberg W, Yeung CY, Ma HK. Hepatitis B infection in infants after neonatal immunization. *Acta Paediatr Jpn*. 1989 Dec;31(6):654-8.

Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. *Lancet*. 1989 Feb 25;1(8635):406-10.

Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, Lu HC, Cheng SH, Wang YF, Wang CY, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. *JAMA*. 1988 Oct 21;260(15):2231-5.

Lo KJ, Lee SD, Tsai YT, Wu TC, Chan CY, Chen GH, Yeh CL. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants born to HBeAg-positive HBsAg-carrier mothers. *Hepatology*. 1988 Nov-Dec;8(6):1647-50.

Farmer K, Gunn T, Woodfield DG. A combination of hepatitis B vaccine and immunoglobulin does not protect all infants born to hepatitis B e antigen positive mothers. *N Z Med J*. 1987 Jul 8;100(827):412-4.

Liu LH. [Comparative study of the efficacy of hepatitis B virus (HBV) vaccine combined with hepatitis B immunoglobulin (HBIG) versus vaccine alone in the interruption of the perinatal transmission of HBV carrier state]. *Zhonghua Liu Xing Bing Xue Za Zhi* 1987;8(6):325-8.

Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. *JAMA*. 1987 May 15;257(19):2597-603.

Oon CJ, Tan KL, Goh KT, Wong-Yong L, Viegas O, McCarthy T, Chan SH, Lee HP. Evaluation of a low dose of hepatitis B vaccine given within a childhood immunisation programme in Singapore. *J Infect*. 1986 Nov;13(3):255-67.

Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA, Altman NL, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med*. 1986 Jul 24;315(4):209-14.

Emini EA, Ellis RW, Miller WJ, McAleer WJ, Scolnick EM, Gerety RJ. Production and immunological analysis of recombinant hepatitis B vaccine. *J Infect*. 1986 Jul;13 Suppl A:3-9.

Yeoh EK, Chang WK, Ip P, Chan KH, Chan E, Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. *J Infect*. 1986 Jul;13 Suppl A:15-8.

Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, Chen RJ, Margolis HS, Huang CH, Maynard JE. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. *Pediatrics*. 1985 Nov;76(5):713-8

Xu ZY, Francis DP, Liu CB, Purcell RH, Duan SC, Chen RJ, et al. Prevention of hepatitis B virus carriage of infants using HBV vaccine in Shanghai. Preliminary report of a randomized double-blind placebo-controlled trial. *Chinese Medical Journal* 1985;98(9):623-6.

Lo KJ, Tsai YT, Lee SD, Yeh CL, Wang JY, Chiang BN, Wu TC, Yeh PS, Goudeau A, Coursaget P, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. *Hepatogastroenterology*. 1985 Apr;32(2):65-8.

Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B

immunoglobulin. Double-blind randomised placebo-controlled study. *Lancet*. 1984 Apr 28;1(8383):921-6.

Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. *Lancet*. 1983 Nov 12;2(8359):1099-102.

Goudeau A, Lo KJ, Coursaget P, Tong MJ, Yeh CL, Tsai YT, Lee JK, Wu TC, Yeh SH, Lee SD. Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers. Preliminary results of active and passive-active immunization. *Dev Biol Stand*. 1983;54:399-404.

Schedule and programmatic issues

Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis a and B vaccine in previous nonresponders to hepatitis B vaccine. *J Infect Dis*. 2008 Aug 1;198(3):299-304.

Ekra D, Herbingier KH, Konate S, Leblond A, Fretz C, Cilote V, Douai C, Da Silva A, Gessner BD, Chauvin P. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d'Ivoire. *Vaccine*. 2008 May 23;26(22):2753-61.

Prymula R, Plisek S. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines. *Expert Opin Biol Ther*. 2008 Apr;8(4):503-13.

Halasa NB, O'Shea A, Shi JR, Lafleur BJ, Edwards KM. Poor Immune Responses to a Birth Dose of Diphtheria, Tetanus, and Acellular Pertussis Vaccine. *J Pediatr*. 2008 Apr 25.

Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. *Pediatrics*. 2008 Mar;121(3):e428-34

Sangfelt P, Uhnöo I, Reichard O, Weiland O. A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. *Scand J Gastroenterol*. 2008;43(4):465-72

Murakami H, Van Cuong N, Huynh L, Hipgrave DB. Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. *Vaccine*. 2008 Mar 10;26(11):1411-9.

Dumolard L et al. Implementation of Newborn Hepatitis B Vaccination - Worldwide, 2006. *Morbidity and Mortality Weekly Report*, 2008, 57:1249-1252.

Wang L, Li J, Chen H, Li F, Armstrong GL, Nelson C, Ze W, Shapiro CN. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. *Bull World Health Organ*. 2007 Sep;85(9):688-94.

Rhiner J, Pfister R, Nassehi Tschopp Y, Bucher HU. Selective immunisation strategy to protect newborns at risk for transmission of hepatitis B: retrospective audit of vaccine uptake. *Swiss Med Wkly.* 2007 Sep 22;137(37-38):531-5.

Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. *J Travel Med.* 2007 Jan-Feb;14(1):9-15.

Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. *Hepatol Res.* 2006 Dec;36(4):265-71.

Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. *Vaccine.* 2006 Jun 29; 24(26): 5509-15.

Jain AK, Mittal SK, Ramji S, Chakravarti A. Hepatitis B vaccine in the EPI schedule. *Indian J Pediatr.* 2005 Aug;72(8):661-4.

Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. *MMWR Recomm Rep.* 2005 Dec 23;54(RR-16):1-31. (

Maayan-Metzger A, Kedem-Friedrich P, Kuint J. To vaccinate or not to vaccinate--that is the question: why are some mothers opposed to giving their infants hepatitis B vaccine? *Vaccine.* 2005 Mar 14;23(16):1941-8.

John TJ, Cooksley G; Steering Committee for the Prevention and Control of Infectious Diseases in Asia. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? *J Gastroenterol Hepatol.* 2005 Jan;20(1):5-10.

Wallace LA, Bramley JC, Ahmed S, Duff R, Hutchinson SJ, Carman WF, Kitchin NR, Goldberg DJ. Determinants of universal adolescent hepatitis B vaccine uptake. *Arch Dis Child.* 2004 Nov;89(11):1041-2.

Gomber S, Sharma R, Ramachandran VG. Immunogenicity of low dose intradermal hepatitis B vaccine and its comparison with standard dose intramuscular vaccination. *Indian Pediatr.* 2004 Sep;41(9):922-6.

Gall SA. Maternal immunization. *Obstet Gynecol Clin North Am.* 2003 Dec;30(4):623-36.

Zuckerman J. The place of accelerated schedules for hepatitis A and B vaccinations. *Drugs.* 2003;63(17):1779-84.

Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. *Pediatrics.* 2003 Jul;112(1 Pt 1):193-8.

- Fisman DN, Agrawal D, Leder K.** The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. *Clin Infect Dis.* 2002 Dec 1;35(11):1368-75.
- Dangio CT, Hall CB.** Timing of vaccinations in premature infants. *BioDrugs.* 2000 May;13(5):335-46.
- Murphy E.** Hepatitis B, vaccination and healthcare workers. *Occup Med (Lond).* 2000 Aug;50(6):383-6.
- Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, Maynard JE.** At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. *Vaccine.* 1999 Oct 14;18(5-6):498-502.
- Kuru U, Turan O, Kuru N, Sağlam Z, Alver A.** Results of vaccinated infants born to HBsAg-positive mothers with different hepatitis B vaccines and doses. *Turk J Pediatr.* 1995 Apr-Jun;37(2):93-102.
- Mangione R et al.** Delayed third hepatitis B vaccine dose and immune response. *Lancet,* 1995, 345: 1111–1112.
- Lee CY, Huang LM, Chang MH, Hsu CY, Wu SJ, Sung JL, Safary A.** The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. *Pediatr Infect Dis J.* 1991 Apr;10(4):299-303.
- Pongpipat D, Suvatte V, Assateerawatts A.** Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. *Asian Pac J Allergy Immunol.* 1989 Jun;7(1):37-40.
- Pongpipat D, Suvatte V, Assateerawatts A.** Hepatitis B immunization in high risk neonates born from HBsAg and HBeAg positive mothers: comparison of standard and low dose regimens. *Asian Pac J Allergy Immunol.* 1988 Dec;6(2):107-10.
- Pongpipat D, Suvatte V, Assateerawatts A.** Efficacy of hepatitis-B immunoglobulin and hepatitis-B vaccine in prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg. *Asian Pac J Allergy Immunol.* 1986 Jun;4(1):33-6.
- Piazza M, Picciotto L, Villari R, Guadagnino V, Orlando R, Isabella L, Macchia V, Memoli AM, Vegnente A, Borrelli AM, et al.** Hepatitis B immunisation with a reduced number of doses in newborn babies and children. *Lancet.* 1985 Apr 27;1(8435):949-51

Duration of protection and booster doses

- Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN.** Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. *Vaccine.* 2009 Mar 13;27(12):1858-1862.

Bialek SR et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. *Pediatric Infectious Diseases Journal*, 2008, 27:881-885.

Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, Lee CY. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. *J Infect Dis.* 2008 May 15;197(10):1419-26.

Ramezani A, Velayati AA, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, Kalantar E, Amirkhani A, Aghakhani A. Persistence of hepatitis B vaccine immunity in hemodialysis patients. *Ther Apher Dial.* 2008 Apr;12(2):143-6.

Poovorawan Y, Hutagalung Y, Chongsrisawat V, Thaemboonlers A, Lefevre I. Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age. *Vaccine.* 2008 Mar 17;26(12):1535-40.

Alavian SM, Mansouri S, Abouzari M, Assari S, Bonab MS, Miri SM. Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005). *Eur J Gastroenterol Hepatol.* 2008 Feb; 20(2):131-4.

Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. *J Infect.* 2008 Nov;57(5):404-9.

Su FH, Chen JD, Cheng SH, Sung KY, Jeng JJ, Chu FY. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. *J Viral Hepat.* 2008 Jan;15(1):14-9.

But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. *Vaccine.* 2008 Oct 1.

Mast EE, Ward JW. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines*, 5th ed., Saunders Elsevier, 2008: 205-241.

Lin CC, Chang CK, Huang YL, Tseng HF. Low seroprevalence of hepatitis B surface antibody among nursing students in Taiwan: an implication for boosting. *Vaccine.* 2007 Dec 12;25(51):8508-11.

Su FH, Huang HY, Chang HJ, Jeng JJ, Liu YH, Chen CD. Forecasting the declining rate of chronic hepatitis-B carrier status at a Taiwanese university: twenty years after implementation of an universal HBV vaccination program in Taiwan. *Chang Gung Med J.* 2007 Nov-Dec;30(6):521-8.

Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, Yang YC, Hung HH, Chu FY. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. *Vaccine.* 2007 Nov 19;25(47):8085-90.

Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. *Vaccine*. 2007 Oct 10;25(41):7160-7.

Hammit LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. *Vaccine*. 2007 Sep 28;25(39-40):6958-64.

Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. *Travel Med Infect Dis*. 2007 May;5(3):171-5.

Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. *Gastroenterology*. 2007 Apr;132(4):1287-93.

van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. *PLoS ONE*. 2007 Aug 15;2(1):e753.

Ribeiro TM, Azevedo RS. Seroconversion of hepatitis B vaccine in infants related to the mother's serostatus in a community of São José dos Campos, state of São Paulo, Brazil. *Clinics*. 2006 Oct;61(5):387-94.

Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. *J Ayub Med Coll Abbottabad*. 2006 Oct-Dec;18(4):4-9.

van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-term protection against carriage of hepatitis B virus after infant vaccination. *J Infect Dis*. 2006 Jun 1;193(11):1528-35.

McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. *Ann Intern Med*. 2005 Mar 1;142(5):333-41.

John TJ, Cooksley G; Steering Committee for the Prevention and Control of Infectious Diseases in Asia. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? *J Gastroenterol Hepatol*. 2005 Jan;20(1):5-10.

Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. *Lancet*. 2005 Oct 15-21;366(9494):1379-84.

Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme

PV. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. *Vaccine*. 2005 Jul 14;23(32):4158-66.

Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, Twu SJ, Su IJ, Huang LM, Lee CY. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. *Hepatology*. 2004 Dec;40(6):1415-20.

Floreani A et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. *Vaccine*, 2004,22: 607-610.

Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. *Indian Pediatr*. 2004 Dec;41(12):1232-7.

Boxall EH, A Sira J, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. *J Infect Dis*. 2004 Oct 1;190(7):1264-9.

Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, Liu CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chen DS, Chang MH. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. *Hepatology*. 2004 Jan;39(1):58-63.

Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. *Clin Gastroenterol Hepatol*. 2004 Oct;2(10):941-5.

Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, Parkinson AJ. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. *Pediatr Infect Dis J*. 2004 Jul;23(7):650-5.

Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. *J Infect Dis*. 2003 Jan 1;187(1):134-8.

Banatvala JE, Van Damme P. Hepatitis B vaccine -- do we need boosters? *J. Viral Hepat*. 2003 Jan;10(1): 1-6.

European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. *Lancet*. 2000 Feb 12;355(9203):561-5.

Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. *Hepatology*. 1999 Mar;29(3):954-9.

Lin DB, Wang HM, Lee YL, Ling UP, Changlai SP, Chen CJ. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. *Vaccine*. 1998 Oct;16(17):1683-7.

Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. *Arch Dis Child Fetal Neonatal Ed.* 1997 Jul;77(1):F47-51.

Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ, Zhuang YL, Xu HF, Qian SG, Zhu QR, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. *J Infect Dis.* 1995 Jan;171(1):54-60.

Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, Chiron JP, Coll-Seck AM, Diop-Mar I. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. *J Hepatol.* 1994 Aug;21(2):250-4.

Zhu QR, Gu XH, Duan SC, Xu HF. Long-term immunogenicity and efficacy of recombinant yeast derived hepatitis B vaccine for interruption of mother-infant transmission of hepatitis B virus. *Chin Med J (Engl).* 1994 Dec;107(12):915-8.

Marion SA, Tomm Pastore M, Pi DW, Mathias RG: Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. *Am J Epidemiol* 1994;140:734-746.

Mintai Z, Kezhou L, Lieming D, Smego RA Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. *Clin Infect Dis.* 1993 Jan;16(1):165-7.

Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, Safary A. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. *Pediatr Infect Dis J.* 1992 Oct;11(10):816-21.

Hepatitis B vaccine combinations

Capeding MR, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. *Bull World Health Organ.* 2008 Jun; 86(6):443-51.

Wong SL, Soosai P, Teoh YL, Han HH, Lefevre I, Bock HL. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia. *Southeast Asian J Trop Med Public Health.* 2008 May;39(3):474-83.

Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E; Protocol 11 study Investigators. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. *Vaccine.* 2008 Jan 30;26(5):686-96.

Lim FS, Han HH, Jacquet JM, Bock HL. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. *Ann Acad Med Singapore.* 2007 Oct; 36(10):801-6.

Bavdekar SB, Maiya PP, Subba Rao SD, Datta SK, Bock HL. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants. *Indian Pediatr.* 2007 Jul;44(7):505-10.

Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Chevart B, Holmes SJ; 085 Study Investigators. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. *J Pediatr.* 2007 Jul;151(1):43-9, 49.e1-2.

Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group, Sanger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. *Vaccine.* 2007 Jan 22;25(6):1055-63.

Omeaca F, Garcia-Sicilia J, Garca-Corbeira P, Boceta R, Romero A, Lopez G, Dal-Re R. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. *Pediatrics.* 2005 Dec;116(6):1292-8.

Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. *Vaccine.* 2005 Jul 1;23(31):4082-7.

Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. *Expert Rev Vaccines.* 2004 Jun;3(3):249-67.

Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. *Rev Panam Salud Publica.* 2002 Oct;12(4):247-57.

Pichichero ME, Blatter MM, Reisinger KS, Harrison CJ, Johnson CE, Steinhoff MC, Senders SD, Rothstein EP, Willems P, Howe BJ. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. *Pediatr Infect Dis J.* 2002 Sep;21(9):854-9

Hep B-vaccine in immunocompromised

Nikolopoulos GK et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. *Clinical Infectious Diseases*, 2009, 48:1763–71.

- Beran J.** Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. *Expert Opin Biol Ther.* 2008 Feb;8(2):235-47
- Kong NC et al.** A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. *Kidney International*,2008,73:856-862.
- de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME.** A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. *J Infect Dis.* 2008 Jan 15;197(2):292-4.
- Shafran SD, Mashinter LD, Lindemulder A, Taylor GD, Chiu I.** Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. *HIV Med.* 2007 Jul;8(5):295-9.
- Kundi M.** New hepatitis B vaccine formulated with an improved adjuvant system. *Expert Rev Vaccines.* 2007 Apr;6(2):133-40.
- Park SD, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, Levine J.** Failure to respond to hepatitis B vaccine in children with celiac disease. *J Pediatr Gastroenterol Nutr.* 2007 pr;44(4):431-5.
- Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP.** Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. *Liver Transpl.* 2007 Mar;13(3):367-73.
- Daryani NE, Nassiri-Toosi M, Rashidi A, Khodarahmi I.** Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case-control study. *World J Gastroenterol.* 2007 Jan 14;13(2):294-8.
- Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE.** Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. *AIDS Res Ther.* 2006 Apr 6;3:9.
- Aziz A, Aziz S, Li DS, Murphy L, Leone N, Kennedy M, Dhillon S, Van Thiel DH.** Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. *J Viral Hepat.* 2006 Apr;13(4):217-21.
- Pasricha N, Datta U, Chawla Y, Singh S, Arora SK, Sud A, Minz RW, Saikia B, Singh H, James I, Sehgal S.** Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. *BMC Infect Dis.* 2006 Mar 30;6:65.
- Godkin A, Davenport M, Hill AV.** Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. *Hepatology.* 2005 Jun;41(6):1383-90.
- Froutan-Pishbijari H, Ghofrani H, Mirmomenm S, Kazemi-Asl S, Nassiri-Toosi M, Farahvash MJ, Toroghi HH, Aminian K, Mansour-Ghanaei F, Bagherzadeh AH.** Immunogenicity of hepatitis B vaccine in multi-transfused thalassemic patients with and

without hepatitis C infection: a comparative study with healthy controls. *Med Sci Monit.* 2004 Dec;10(12):CR679-83.

Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. *Aliment Pharmacol Ther.* 2004 Nov 15;20(10):1053-62.

Schroth RJ, Hitchon CA, Uhanova J, Noreddin A, Taback SP, Moffatt ME, Zacharias JM. Hepatitis B vaccination for patients with chronic renal failure. *Cochrane Database Syst Rev.* 2004;(3):CD003775.

Saari TN; Immunization of preterm and low birth weight infants. *American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics.* 2003 Jul;112(1 Pt 1):193-8.

Rich JD et al. A review of the case for hepatitis B vaccination of high-risk adults. *American Journal of Medicine,* 2003,114:316-318.

Losonsky GA et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. *Paediatrics,* 1999,103:E1.

Therapeutic use of hepatitis B-vaccines

Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. *Vaccine.* 2007 Dec 12;25(51):8585-97.

Ishikawa T, Kakumu S. Use of hepatitis B vaccine for the treatment of chronic hepatitis B. *Hepatol Res.* 2007 Oct;37 Suppl 3:S347-50.

Vaccine associated adverse events

de Carvalho JF, Shoenfeld Y. Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination. *Eur J Intern Med.* 2008 Jul;19(5):383-5.

WHO Global Advisory Committee on Vaccine Safety, 12-13 December 2007. *Wkly Epidemiol Rec.* 2008 Jan 25;83(4):37-44. English, French. No abstract available.

(WHO 2003-2008) http://www.who.int/vaccine_safety/topics/hepatitisb/en/index.html

Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. *Vaccine.* 2007 Dec 12;25(51):8585-97.

Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. *Arch Pediatr Adolesc Med.* 2007 Dec;161(12):1176-82.

Mikaeloff Y et al. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. *Brain.* 2007;130:1105-1110.

Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. *J Acquir Immune Defic Syndr.* 2007 Nov 1;46(3):279-82.

Yu O, Bohlke K, Hanson CA, Delaney K, Rees TG, Zavitkovsky A, Ray P, Mullooly J, Black SB, Benson P, Thompson WW, Davis RL, Jackson LA. Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. *Pharmacoepidemiol Drug Saf.* 2007 Jul;16(7):736-45.

Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S; KIDSEP study group of the French Neuropaediatric Society. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. *Brain.* 2007 Apr;130(Pt 4):1105-10.

Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B; The 013 Study Group for ProQuad. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined *Haemophilus influenzae* type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *Pediatr Infect Dis J.* 2006 Apr;25(4):287-92.

Woo EJ, Miller NB, Ball R; VAERS Working Group. Adverse events after hepatitis A B combination vaccine. *Vaccine.* 2006 Mar 24;24(14):2685-91.

Meriste S, Lutsar I, Tamm E, Willems P. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. *Scand J Infect Dis.* 2006;38(5):350-6.

Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. *Clin Exp Rheumatol.* 2004 Nov-Dec;22(6):749-55.

Luman ET, Fiore AE, Strine TW, Barker LE. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage. *JAMA.* 2004 May 19;291(19):2351-8.

Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. *Neurology.* 2004 Sep 14;63(5):838-42.

Eriksen EM, Perlman JA, Miller A, Marcy SM, Lee H, Vadheim C, Zangwill KM, Chen RT, DeStefano F, Lewis E, Black S, Shinefield H, Ward JI. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project. *Pediatr Infect Dis J.* 2004 Jul;23(7):656-62.

Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, Schuerman L, Sanger R. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. *Vaccine*. 2004 Jun 2;22(17-18):2226-33.

Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. *Expert Opin Drug Saf*. 2003 May;2(3):225-31.

DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. *Expert Rev Vaccines*. 2002 Dec;1(4):461-6.

Jefferson T, Traversa G. Hepatitis B vaccination: risk-benefit profile and the role of systematic reviews in the assessment of causality of adverse events following immunisation. *J Med Virol*. 2002 Jul;67(3):451-3.

Cost and Cost-effectiveness of Hep B vaccination

Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. *Am J Prev Med*. 2008 Jul;35(1):25-32.

Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. *Bull World Health Organ*. 2007 Nov;85(11):833-42

Griffiths UK, Hutton G, Das Dores Pascoal E. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. *Health Policy and Planning*, 2005, 20:50-59.

Levin CE et al. The costs of home delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in Indonesia. *Bulletin of the World Health Organization*, 2005, 83:456-61.

Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pechevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. *Pharmacoeconomics*. 2002;20(1):1-7.

Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness. *Australian and New Zealand Journal of Public Health*, 2001,25):222-229.

Margolis HS et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. *Journal of the American Medical Association* 1995,274:1201-1208.

Hepatitis B immunoglobulin

WHO Scientific Advisory Group of Experts. Report in Weekly Epidemiological Record 2009, 84, 213-236.

Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. *Hepatology* 1983; 3(2):135–41.

Beasley RP, Hwang LY, Szmuness W, Stevens CE, Lin CC, Hsieh FJ, et al. HBIG prophylaxis for perinatal HBV infections - final report of the Taiwan trial. *Developmental Biology Standard* 1983;54:363–75.